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Abstract  
Complete response (CR) was an uncommon event in elderly myeloma patients until 
novel agents were combined with standard oral melphalan-prednisone. This analysis 
assesses the impact of treatment response on progression-free survival (PFS) and overall 
survival (OS). We retrospectively analysed 1,175 newly diagnosed myeloma patients, 
enrolled in 3 multicentre trials, treated with melphalan-prednisone alone (n=332), melphalan-
prednisone-thalidomide (n=332), melphalan-prednisone-bortezomib (n=257) or melphalan-
prednisone-bortezomib-thalidomide (n=254). After a median follow-up of 29 months, the 3-
year PFS and OS were 67% and 27% (HR 0.16; p<0.001), and 91% and 70% (HR 0.15; 
p<0.001) in patients who obtained CR and in those who achieved very good partial response 
(VGPR) respectively. Similar results were observed in patients older than 75 years. 
Multivariate analysis confirmed that the achievement of CR was an independent predictor of 
longer PFS and OS, regardless of age, International Staging System stage and treatment. 
These findings highlight a significant association between the achievement of CR and long-
term outcome, and support the use of novel agents to achieve maximal response in elderly 
patients, including those over 75 years. 
 
Introduction 
Multiple myeloma (MM) is an incurable plasma-cell neoplasm. The main goal of 
treatment is to improve progression-free survival (PFS) and overall survival (OS). The 
International Staging System (ISS) classification and the cytogenetic status are the most 
relevant prognostic factors.1-4 In patients eligible for high-dose therapy and autologous 
transplantation the achievement of complete response (CR)5,6 or at least very good partial 
response (VGPR),7 is associated with prolonged PFS and OS. In patients not eligible for 
autologous transplantation, CR was quite rare until the novel agents thalidomide or 
bortezomib were added to conventional chemotherapies. Five trials reported an 
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improvement in PFS with the combinations melphalan-prednisone-thalidomide (MPT) 
compared with melphalan-prednisone (MP), but in only two of them this translated into an 
increase in OS.8-13 A randomized trial that compared melphalan-prednisone-bortezomib 
(VMP) with MP showed an improvement in both PFS and OS with the three-drug 
combination.14,15  The four-drug combination melphalan-prednisone-thalidomide-bortezomib 
followed by bortezomib-thalidomide maintenance (VMPT-VT) was superior to the novel 
combination VMP.16 The CR rates were in the range of 3-4% with MP,8-15 6-16% with MPT,8-
13 24-33% with VMP14,15,16 and raised to 38% with VMPT-VT.16 
In this study we compared PFS and OS of newly diagnosed patients who achieved 
CR after MP, MPT, VMP or VMPT-VT to those whose best response was VGPR or partial 
response (PR) only.  
 
Material and methods 
Study design 
Patients with newly diagnosed MM, not eligible for high-dose therapy and autologous 
transplantation due to age (≥ 65 years) or coexisting comorbidities, enrolled in the GISMM-
2001 MP vs MPT, the HOVON MP vs MPT, and the GIMEMA MM0305 VMP vs VMPT-VT 
phase III trials were retrospectively analyzed. Details on treatment regimens and results of 
these studies have previously been reported.
8,12,13,16
 Briefly, 331 patients were randomly 
assigned to receive 6 courses of MP or MPT followed by maintenance with thalidomide until 
progression;
8
 344 to receive 8 courses of MP or MPT followed by maintenance with 
thalidomide until progression;
12 and 511 to receive 9 cycles of VMP or VMPT followed by 
continuous VT as maintenance.
16 
Trials were approved by the Independent Ethics 
Committees/Institutional Review Boards at all participating centers. Patients provided written 
informed consent before entering the studies, which were performed in accordance with the 
Declaration of Helsinki and registered at ClinicalTrials.gov, numbers NCT00232934, 
ISRCTN 90692740 and NCT01063179. Patients who received at least one dose of the study 
drug and for whom best response to treatment was available were included in this analysis.  
 
Assessment 
In the GISMM-2001 MP vs MPT and in the HOVON MP vs MPT studies responses 
were initially determined by investigator assessment using the European Group for Blood 
and Marrow Transplantation criteria.17 All responses were confirmed at least in two 
consecutive assessments six weeks apart. In the GIMEMA MM0305 VMP vs VMPT-VT 
responses were initially determined by investigator assessment using the International 
Myeloma Working Group criteria.18,19 All responses were confirmed at least in two 
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consecutive assessments made at any time. In this retrospective analysis, responses of 
patients enrolled in the GISMM-2001 MP vs MPT, and the HOVON MP vs MPT were re-
evaluated using the International Myeloma Working Group criteria.18,19  Briefly, a PR was 
defined as a 50% or higher decrease in the serum monoclonal protein (M-protein) levels 
from baseline and a reduction 90% or greater in 24-hour urine M-protein excretion or < 200 
mg/24h; for patients with soft tissue plasmacytomas, a 50% or higher reduction was 
required. A VGPR required a 90% or greater reduction in serum M-protein and urinary M-
protein less than 100 mg/24h or M-protein detectable by immunofixation but not by 
electrophoresis. A CR was defined as negative serum and urine immunofixation, 
disappearance of any soft tissue plasmacytoma and less than 5% plasma cells on bone 
marrow examination. Disease that did not satisfy the criteria for PR, VGPR, CR or 
progressive disease (PD) was classified as stable disease (SD). Disease progression 
required any of the following: 25% or greater increase from lowest response value in serum 
M-protein (absolute ≥ 0.5 g/dl) or urine M-protein (absolute ≥ 200 mg/24h). 
PFS was calculated from the time of diagnosis until the date of progression, relapse, 
death from any cause, or the date the patient was last known to be in remission. OS was 
calculated from the time of diagnosis until the date of death or the date the patient was last 
known to be alive. Duration of CR was calculated from the time of CR achievement until the 
date of progression, relapse, death from any cause, or the date the patient was last known 
to be in remission. 
 
Statistical analysis  
Data cut-off was May 1, 2010. For this retrospective non pre-planned analysis, 
patients treated with MP, MPT, VMP or VMPT-VT were pooled together and stratified 
according to best response achieved. Patient characteristics were compared using the 
Pearson chi-square test for discrete variables or the Mann-Whitney test for continuous 
variables. PFS, OS and duration of CR were estimated according to the Kaplan–Meier 
method and analyzed by univariate and multivariate Cox proportional hazards models, 
comparing the two arms by the Wald test and calculating 95% confidence intervals (CIs). A 
landmark analysis with landmark point at 6 months was performed. The following variables 
were assessed for potential association with PFS and OS: age at diagnosis (>75 vs. ≤75 
yrs), gender, Durie-Salmon and ISS stages, baseline creatinine (>1.2 vs. ≤1.2 mg/dl), 
treatment regimen (MP/MPT/VMP/VMPT-VT) and best response achieved 
(CR/VGPR/PR/SD/PD). Best response was always treated as a time-dependent variable. All 
reported P values were two-sided, at the conventional 5% significance level.  
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Results 
Patients  
A total of 1,175 patients were retrospectively analysed; 332 received MP, 332 MPT, 
257 VMP and 254 VMPT-VT. Best response to treatment was available in 1,136: CR was 
reported in 195 (17%), VGPR in 212 (19%), PR in 397 (35%); the remaining patients 
achieved less than PR. Baseline demographics and disease characteristics were similar in 
patients who obtained CR, VGPR, PR or in the entire study population. Patients older than 
75 years were 29% in the PR group, 21% in the VGPR group and 21% in the CR group. 
Patients with ISS stage I, II, and III were equally distributed in the CR, VGPR or PR groups. 
Response rates varied according to treatment regimens and accordingly the proportion of 
patients treated with MP, MPT, VMP, or VMPT-VT was different in the CR, VGPR and PR 
groups. In the CR group 49% of patients received VMPT-VT, 31% VMP, 15% MPT and only 
5% MP; in the VGPR group, 25% received VMPT-VT, 31% VMP, 32% MPT and 13% MP; in 
the PR group, 19% received VMPT-VT, 20% VMP, 32% MPT and 29% MP  (Table 1).  
 
Impact of CR on outcome 
After a median follow-up of 29 months (range 1-81 months), 3-year PFS and OS for 
the entire study population were 29% and 65%, respectively. The 3-year PFS was 67% in 
patients who achieved CR, 27% in patients with VGPR (HR 0.16, 95% CI 0.10-0.24, P < 
0.001) and 27% in those with PR only (HR 0.07, 95% CI 0.04-0.13, P < 0.001) (Figure 1A). 
Similarly, the 3-year OS was 91% in patients who obtained CR, 70% in patients with VGPR 
(HR 0.15, 95% CI 0.08-0.28, P < 0.001), and 67% in those with PR only (HR 0.08, 0.04-0.16, 
P < 0.001), (Figure 1B). A landmark analysis for PFS and OS, with landmark point at 6 
months, was performed:  patients who achieved CR had prolonged PFS and OS compared 
with patients who achieved VGPR and PR only (Figure 1C and 1D).  
The 3-year PFS was 26% in patients older than 75 years and 29% in those 75 years 
or younger (HR 1.23, 95% CI 1.04-1.45, P = 0.014), while the 3-year OS was 54% and 65% 
(HR 1.59, 95% CI 1.29-1.96, P < 0.001). However, the impact of CR on both PFS and OS 
was similar in patients older or younger than 75 years. In the analysis restricted to patients 
older than 75 years, the 3-year PFS was 79% in patients who achieved CR whereas 24% in 
those who obtained VGPR (HR 0.26, 95% CI 0.12-0.58, P = 0.001) and 23% in those who 
attained PR (HR 0.20, 95% CI 0.10-0.41, P < 0.001), (Figure 2A). The 3-year OS was 88% 
in patients who achieved CR, 65% in those who reached VGPR (HR 0.13, 95% CI 0.03-0.58, 
P = 0.007) and 57% in those who obtained PR (HR 0.12, 95% CI 0.03-0.51, P = 0.004), 
(Figure 2B). 
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Subgroup analysis of OS in CR patients according to treatment regimen (bortezomib 
vs non-bortezomib regimens) was performed. There were no significant differences in PFS 
between the 2 groups (HR 0.67, 95% CI 0.34-1.32, P = 0.248), whereas there was a trend 
towards a better OS for bortezomib patients compared to non-bortezomib patients (HR 0.31, 
95% CI 0.08-1.29, P = 0.107). 
Achievement of CR and longer OS with the use of highly efficacious regimens may 
lead to greater toxicity. We therefore analyzed the toxicities in patients who achieved CR, 
VGPR and PR. There were no significant differences in rate of grade 3-4 adverse events in 
patients who obtained CR, VGPR or PR. In particular, rate of grade 3-4 peripheral 
neuropathy was 10% in patients who achieved CR, 13% in patients who obtained VGPR, 
and 10% in those who attained PR.  
 
Impact of time to CR on outcome 
Overall, most CRs were reached during the first 6 months of therapy: 34% at 4 
months, 62% at 6 months and 85% at 9 months of therapy. There were no significant 
differences in either PFS (HR 1.06, 95% CI 0.49-2.27, P = 0.878) or OS (P = 0.676) or 
duration of CR (HR 0.66, 95% CI 0.30-1.45, P = 0.305) between patients who achieved CR 
during the first 6 months of therapy or later.   
 
Multivariate analysis 
Multivariate analysis was performed on the 681 patients for whom complete baseline 
assessment and data on best response were available. The achievement of CR was the 
dominant factor associated with significantly longer PFS as compared to VGPR (HR 0.22; 
95% CI 0.13-0.38; P < 0.001) and PR (HR 0.13; 95% CI 0.07-0.26; P < 0.001), regardless of 
baseline patient characteristics, staging and treatment administered. Age > 75 years was not 
associated with shorter PFS (HR 1.14; 95% CI 0.93-1.40; P = 0.220), whereas ISS stage II 
and III were. The addition of bortezomib or thalidomide to MP correlated with a significant 
improvement in PFS (Table 2). Similarly, the achievement of CR was the variable most 
strongly associated with significantly prolonged OS as compared to VGPR (HR 0.25, 95% CI 
0.11-0.55, P = 0.001) and PR (HR 0.16, 95% CI 0.06-0.39, P < 0.001). There was a trend for 
shorter OS for age > 75 years (HR 1.30, 95% CI 1.00-1.70, P = 0.053). The addition of 
bortezomib or bortezomib-thalidomide to MP was associated with longer OS, whereas the 
addition of thalidomide only was not (Table 3).  
   
Discussion  
The addition of bortezomib or thalidomide to standard oral MP has dramatically 
increased CR rates, and extended PFS and OS.8-16 We performed a retrospective analysis 
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on pooled data of 1,175 elderly patients with newly diagnosed MM, treated with MP and 
novel agents. The median survival of the entire population was 50 months, significantly 
longer than 29 months previously reported in a large meta-analysis of 6,633 patients (58% of 
them younger than 65 years of age) who received MP or conventional chemotherapy.20 The 
achievement of CR was associated with improved PFS and OS: the 3-year PFS was 67% in 
patients who achieved CR and 27% in those in VGPR or PR, while the 3-year OS rates were 
91% in patients who obtained CR and 67-70% in those in VGPR or PR. Similar impact of CR 
was observed in patients over 75 years.  
In younger patients treated with conventional chemotherapy without novel agents, 
the achievement of CR significantly prolonged OS when compared to the achievement of PR 
only.21 In elderly patients treated with VMP in the VISTA phase III trial, CR was associated 
with a significantly improved time to progression when compared to VGPR and PR. 
However, no significant differences in OS were reported, probably due to the small sample 
size of the study.22 In our analysis, the achievement of CR predicted long-term outcome. 
This finding is consistent with a large meta-analysis of 4,990 younger patients who 
underwent autologous transplantation,23 and with the post-hoc analysis of elderly patients 
treated with VMP in the VISTA trial.22 Of notice, it may be difficult to accurately assess a 
serum M-protein decrease higher than 90% in patients with small M-protein size at 
diagnosis. Therefore, in some cases, response could be underestimated. This should be 
considered while comparing outcome of patients who achieved VGPR or PR. When VGPR 
and CR were pooled together, their achievement significantly improved outcome if compared 
to PR only. In clinical practice, the achievement of CR rather than VGPR correlates with 
improved outcome. 
In our study, the impact of CR on long-term outcome has been confirmed regardless 
of baseline patient characteristics including age. In the era of novel agents, CR has become 
an achievable goal not only in young but also in elderly patients. The increased life 
expectancy of the general population and the better performance status of many aged 
patients should change the treatment paradigm, with a significant shift from a more palliative 
therapy to a more effective intensive approach. In previous studies, an increased response 
rate did not translate into an increased OS, particularly in patients older than 70-75 years, 
where treatment related toxicities greatly impaired efficacy.9,24-26 Highly efficacious regimens 
may be associated with higher toxicity and this should be carefully considered. The toxicity 
profile related to the treatment regimens evaluated in this analysis have been published 
elsewhere.8,12,13,16 We did not find any significant difference in rate of grade 3-4 adverse 
events in patients who obtained CR, VGPR or PR. In the present analysis, the higher CR 
rate has been reported with the Bortezomib combinations. In the VMPT-VT vs VMP 
GIMEMA study, the protocol was amended and Bortezomib schedule was reduced from 
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twice- to once-weekly infusions in order to decrease toxicity. Extra-hematologic grade 3-4 
adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly 
patients (P = 0.003) and the incidence of grade 3-4 peripheral neuropathy was 8% in the 
once-weekly and 28% in the twice-weekly group (P < 0.001). A post-hoc analysis assessed 
the impact of the schedule change on efficacy and safety. The treatment schedule change 
did not adversely impact on efficacy, since long-term outcomes and CR rates were similar 
between once-weekly and twice-weekly patients.28  Our retrospective analyses suggest that 
efficacy (high CR rate) and feasibility (weekly administration of Bortezomib,16,28 low-dose  
thalidomide8,10,12,13,16) are both essential to improve outcome in frail and very elderly patients. 
The achievement of CR correlates with improved outcome regardless of patient age, 
whereas individual dose-adjustments should be adopted to minimize excessive toxicities that 
in turn jeopardize efficacy.  
There is a correlation between rate of CR and treatment. Both factors impact on 
outcome. Subgroup analysis of outcome in CR patients who received bortezomib vs patients 
who did not showed no differences in PFS, but a trend toward a better OS in bortezomib-
treated patients was seen. Unfortunately, this analysis has some limitations: patients who 
received bortezomib regimens accounted for 80% of the CRs, whereas non-bortezomib 
regimens accounted for 20% of the CRs; median follow-up for bortezomib patients was 24 
months, whereas for non-bortezomib patients it was 39 months; and a limited number of 
events occurred.   
By multivariate analysis, the association of the achievement of CR with better 
outcome was independent of ISS stage: patients with either stage II-III or stage I disease 
benefited from profound cyto-reduction. Moreover, the addition of bortezomib, but not of 
thalidomide only, was associated with longer OS. As previously reported, combinations 
including MP plus bortezomib were correlated with a significant improvement in OS14,15,16 
while combinations including MP plus thalidomide failed to show such advantage.8,11-13 
Comparing the clinical outcomes of the treatment regimens employed in the 3 trials shows 
however some limitations given the lack of a direct randomised comparison, differences in 
treatment schedules and length of follow-up. Unfortunately, complete baseline data were not 
available for all patients, and the multivariate analysis was consequently performed on 681 
of 1,175 patients. Moreover, data on chromosomal abnormalities were not available for the 
majority of patients, and these variables were not included in the multivariate analysis. 
In our study, 34% of CRs were reported at 4 months of treatment, 62% at 6 months 
and 85% at 9 months, suggesting that 9 months could be considered a reasonable length of 
induction therapies. The long term advantages linked with the achievement of CR were 
similar in patients who obtained it before or after the first 6 months of therapy. These results, 
consistent with previous findings,22,27 support the need to identify an optimal length of 
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treatment and to adjust its intensity to prevent toxicities and early discontinuation in elderly 
patients.  
Free-light chain assay, multiparameter flow cytometry and polymerase chain reaction 
have recently been employed to define more stringent response criteria.29,30 The greater 
depth of response, detectable with these more sensitive techniques as compared to 
standard immunofixation, could further help clinicians to set the optimal level of response 
and individualise treatment intensity and duration.  
Consolidation and maintenance therapy can improve outcome. Consolidation after 
autologous transplantation with bortezomib-thalidomide-dexamethasone improved the CR 
rate.29 Maintenance treatment with lenalidomide improved PFS in younger and elderly 
patients.31,32 Ideally, treatment strategies should include induction regimens associated with 
the highest CR rate followed by maintenance treatment.  
In conclusion, the achievement of CR was an independent predictor of long-term 
outcome regardless of age, and International Staging System stage. These findings support 
the use of novel agents to achieve maximal response even in elderly patients.  
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Tables 
 
Table 1. Patient demographics and baseline characteristics 
Variable 
All 
patients  
(n=1175) 
CR 
(n=195) 
VGPR  
(n=212) 
PR 
(n=397) 
Gender     
Male 613 (52) 89 (46) 105 (50) 217 (55) 
     
Age     
Median-years 72 71 71 72 
range-years 54-89 54-86 61-85 56-87 
>75 years 314 (27) 40 (21) 44 (21) 117 (29) 
     
International Staging System stage*     
I 223 (25) 43 (28) 39 (24) 90 (29) 
II 430 (48) 74 (47) 79 (49) 149 (47) 
III 241 (27) 39 (25) 43 (27) 75 (24) 
Missing 281  - - - 
     
Durie and Salmon Staging System stage*     
II 298 (32) 34 (30) 41 (26) 113 (35) 
III 622 (68) 78 (70) 117 (74) 206 (65) 
Missing 255  - - - 
     
Creatinine*     
> 1.2  mg/dl 353 (30) 48 (25) 71 (33) 110 (28) 
Missing 3 - - - 
     
Therapy     
MP 332 (28) 9 (5) 27 (13) 117 (29) 
MPT 332 (28) 30 (15) 67 (32) 127 (32) 
VMP 257 (22) 61 (31) 65 (31) 79 (20) 
VMPT-VT 254 (22) 95 (49) 53 (25) 74 (19) 
*percentage calculated on number of patients whose data were available  
Data are number and %. N= number; CR, complete response; VGPR, very good partial response; PR, 
partial response; MP, melphalan-prednisone; MPT, melphalan-prednisone-thalidomide; VMP, 
bortezomib-melphalan-prednisone; VMPT-VT, bortezomib-melphalan-prednisone-thalidomide followed 
by bortezomib-thalidomide maintenance. 
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Table 2: Univariate and multivariate analysis (Cox model) of progression-free survival 
  Univariate   Multivariate  
 HR 95% CI P value  HR 95% CI P value 
        
Response*   <0.001    <0.001 
CR vs. VGPR 0.16 0.10-0.24 <0.001  0.22 0.13-0.38 <0.001 
CR vs. PR 0.07 0.04-0.13 <0.001  0.13 0.07-0.26 <0.001 
CR vs. SD 0.03 0.01-0.05 <0.001  0.06 0.03-0.12 <0.001 
CR vs. PD 0.007 0.003-0.01 <0.001  0.02 0.007-0.04 <0.001 
      
Age      
>75 vs. <75 1.23 1.04-1.45 0.014  1.14 0.93-1.40 0.220 
       
ISS   <0.001   0.016 
II vs. I 1.45 1.17-1.81 0.001  1.36 1.06- 1.74 0.015 
III vs. I 1.59 1.24-2.03 <0.001  1.47 1.12-1.95 0.006 
      
D&S Stage      
III vs. II 1.31 1.10-1.756 0.003  1.33 1.08-1.63 0.007 
       
Therapy   <0.001   <0.001 
MPT vs. MP 0.70 0.59-0.84 <0.001  0.78 0.63-0.98 0.029 
VMP vs. MP 0.42 0.34-0.53 <0.001  0.52 0.35- 0.76 0.001 
VMPT-VT vs. MP 0.27 0.21-0.36 <0.001  0.51 0.35-0.75 0.001 
*treated as a time-dependent variable 
CR, complete response; VGPR, very good partial response PR, partial response; SD, stable disease; PD, 
progressive disease; ISS, International Staging System; D&S, Durie and Salmon staging system; MP, 
melphalan-prednisone; MPT, melphalan-prednisone-thalidomide; VMP, bortezomib-melphalan-
prednisone; VMPT-VT, bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-
thalidomide maintenance. 
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Table 3: Univariate and Multivariate analysis (Cox model) of overall survival 
  Univariate   Multivariate  
 HR 95% CI P value  HR 95% CI P value 
       
Response*   <0.001   <0.001 
CR vs. VGPR 0.15 0.08-0.28 <0.001  0.25 0.11-0.55 0.001 
CR vs. PR 0.08 0.04-0.16 <0.001  0.16 0.06-0.39 <0.001 
CR vs. SD 0.03 0.01-0.06 <0.001  0.07 0.02-0.20 <0.001 
CR vs. PD 0.01 0.005-0.03 <0.001  0.03 0.009-0.11 <0.001 
      
Age      
>75 vs. <75 1.59 1.29-1.96 <0.001  1.30 1.00-1.70 0.053 
       
ISS   <0.001   <0.001 
II vs. I 1.73 1.24-2.43 0.001  1.41 0.99- 2.01 0.056 
III vs. I 2.84 2.00-4-04 <0.001  2.17 1.49-3.15 <0.001 
      
D&S Stage      
III vs. II 1.38 1.10-1.73 0.006  1.38 1.04- 1.82 0.024 
       
Therapy   <0.001   0.003 
MPT vs. MP 0.88 0.71-1.10 0.263  1.00 0.76-1.31 0.991 
VMP vs. MP 0.25 0.17-0.38 <0.001  0.30 0.14- 0.64 0.002 
VMPT-VT vs. MP 0.23 0.15-0.36 <0.001  0.50 0.26-0.95 0.035 
*treated as a time-dependent variable 
CR, complete response; VGPR, very good partial response PR, partial response; SD, stable disease; PD, 
progressive disease; ISS, International Staging System; D&S, Durie and Salmon staging system; MP, 
melphalan-prednisone; MPT, melphalan-prednisone-thalidomide; VMP, bortezomib-melphalan-
prednisone; VMPT-VT, bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-
thalidomide maintenance. 
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Figure  Legends:  
 
Figure 1. Panel A. Progression-free survival in patients achieving complete response 
(CR), very-good partial response (VGPR) and partial response (PR). Panel B. Overall 
survival in patients achieving CR, VGPR and PR. Panel C. Landmark analysis of 
progression-free survival (landmark point at 6 months) in patients achieving CR, 
VGPR and PR. Panel D. Landmark analysis of overall survival (landmark point at 6 
months) in patients achieving CR, VGPR and PR. 
Figure 2. Panel A. Progression-free survival in patients older than 75 years achieving 
complete response (CR), very-good partial response (VGPR) and partial response 
(PR). Panel B. Overall survival in patients older than 75 years achieving CR, VGPR and 
PR. 
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